The National Institutes of Health stopped the trial after an independent safety board concluded that the drug was unlikely to benefit patients.
Published: June 20, 2020 at 08:21PM
from NYT Health https://ift.tt/2zPBMVh
The National Institutes of Health stopped the trial after an independent safety board concluded that the drug was unlikely to benefit patients.
Published: June 20, 2020 at 08:21PM
from NYT Health https://ift.tt/2zPBMVh